The highest drop is 97%!

In the middle of the night on July 12, the results of the seventh batch of centralized procurement plans focusing on medical professionals across the country were quietly releas.

The average price reduction is 48%, and the maximum price reduction is 97%

The average price of the drugs to be selected is reduced by 48%; it is the same as the special centralized procurement of insulin, but the decline is moderated compared with the first five batches of centralized procureme.

However, in terms of the highest price reduction, the highest price reduction of drugs is still 97%, which is still a battle of drug pric.

According to the drug price of Yaoz.

In addition, there are 15 products whose prices have been reduced by more than 900%, namely Clindamycin Phosphate Injection, Tenofovir Fumarate, Edaravone Injection, Palonosetron Hydrochloride Injection and Tirofiban Hydrochloride Sodium Chloride Injecti.

Among them, Longze Pharmaceutical, Qilu Pharmaceutical, Suzhou Terui, Shanghai Desano, China Resources Sanjiu, Jilin Sihuan Pharmaceutical, Huabei Pharmaceutical and Anke Hengyi Pharmaceutical are 8 compani.

According to Yaoz.

In terms of the minimum unit price of preparations, 2 varieties fell below the floor price, and the price to be selected was less than 1

Compared with the previous national procurement, there are many quotations from companies with a unit price of less than 1000 yu.

It is also worth noting that the seventh batch of collections included 29 injections, accounting for 45

Among them, omeprazole injection is the most popular product in the country, showing a "27+1" competition patte.

According to the sales database of Yaozhi Hospital, the sales of omeprazole sodium for injection in domestic sample hospitals in 2021 will reach 334 yuan, of which Jiangsu Osaikang accounts for 449%, and this species is not on the list of successful bidde.

More than 10 varieties of companies won the bid

Qilu, Yangzijiang, Kel.

As for the successful bidders, 488 products from 295 companies participated in the bidding, and 327 products from 217 companies were eligible to be select.

       Qilu Pharmaceutical won the bid with the largest number of bids, with 17 products shortlisted and 16 products won the bid; followed by Yangzijiang Pharmaceutical with 12 products won the bid, Kelun Pharmaceutical and Sinopharm Group won the bid with 11 and 10 products respective.

       As a large generic drug maker, Qilu Pharma has been the most eye-catching one in the past centralized procureme.

       Epilogue

       This collection is still "internal volume" inten.

However, the reduction in drug prices has also brought benefits to patien.

According to China News Network, 60 kinds of drugs were successfully purchased in this centralized procureme.

According to the agreed procurement volume, it is estimated that the annual cost savings will be 15 billion yu.

It can be seen that with the continuous advancement of the reform of centralized procurement with volume, the artificially high medical prices are constantly being squeezed o.